PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8264567-1 1993 Acute treatment of rats with recombinant tumour necrosis factor (TNF-alpha) caused an enhanced proteolytic rate--measured as tyrosine released in the presence of cycloheximide-in soleus muscle (34%). Cycloheximide 162-175 tumor necrosis factor Rattus norvegicus 65-74 8788263-8 1996 The LPS- and TNF-induced increase in arginine transport activity was blocked by cycloheximide and actinomycin D, indicating the requirement for RNA and protein synthesis. Cycloheximide 80-93 tumor necrosis factor Rattus norvegicus 13-16 8559306-2 1995 The antitumor activity of TNF-alpha against C6 cells was partially inhibited by actinomycin D and cycloheximide, suggesting that it is possibly dependent upon new ribonucleic acid and protein synthesis. Cycloheximide 98-111 tumor necrosis factor Rattus norvegicus 26-35 7536096-15 1995 Inhibition of protein synthesis with cycloheximide (Cx) abolished the loss in function that occurred over 2h in both control and IL-1 beta plus TNF-a-treated hearts.7. Cycloheximide 37-50 tumor necrosis factor Rattus norvegicus 144-149 7536096-15 1995 Inhibition of protein synthesis with cycloheximide (Cx) abolished the loss in function that occurred over 2h in both control and IL-1 beta plus TNF-a-treated hearts.7. Cycloheximide 52-54 tumor necrosis factor Rattus norvegicus 144-149 7530691-7 1994 was stimulated by the cytokines interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha), an effect enhanced by endotoxin [lipopolysaccharide (LPS)], reduced by the competitive inhibitor of L-arginine metabolism, NG-monomethyl-L-arginine (L-NMMA) and inhibited by cycloheximide. Cycloheximide 281-294 tumor necrosis factor Rattus norvegicus 95-104 1499941-4 1992 Cotreatment of cells exposed to LPS or TNF-alpha with actinomycin D or cycloheximide showed that de novo transcription but not protein synthesis is required for the LPS- and TNF-alpha-dependent induction in MnSOD mRNA. Cycloheximide 71-84 tumor necrosis factor Rattus norvegicus 39-48 1444645-7 1992 Inhibition of protein synthesis by cycloheximide as well as addition of cyclic adenosine monophosphate synergistically enhanced the suppression of mitochondrial respiration by TNF alpha, resulting in complex I activity of 6.9 +/- 1.6% and 24.9 +/- 2.9% of that of untreated cells. Cycloheximide 35-48 tumor necrosis factor Rattus norvegicus 176-185 1460280-5 1992 De novo protein synthesis is not required for TNF-alpha expression because the inclusion of cycloheximide does not prevent expression of the gene and acts to superinduce TNF-alpha mRNA levels. Cycloheximide 92-105 tumor necrosis factor Rattus norvegicus 170-179 1460280-7 1992 Cycloheximide acts to increase both transcription of the TNF-alpha gene and stability of TNF-alpha mRNA thereby resulting in increased TNF-alpha steady state mRNA levels. Cycloheximide 0-13 tumor necrosis factor Rattus norvegicus 57-66 1460280-7 1992 Cycloheximide acts to increase both transcription of the TNF-alpha gene and stability of TNF-alpha mRNA thereby resulting in increased TNF-alpha steady state mRNA levels. Cycloheximide 0-13 tumor necrosis factor Rattus norvegicus 89-98 1460280-7 1992 Cycloheximide acts to increase both transcription of the TNF-alpha gene and stability of TNF-alpha mRNA thereby resulting in increased TNF-alpha steady state mRNA levels. Cycloheximide 0-13 tumor necrosis factor Rattus norvegicus 89-98 1499941-4 1992 Cotreatment of cells exposed to LPS or TNF-alpha with actinomycin D or cycloheximide showed that de novo transcription but not protein synthesis is required for the LPS- and TNF-alpha-dependent induction in MnSOD mRNA. Cycloheximide 71-84 tumor necrosis factor Rattus norvegicus 174-183 3031163-3 1987 However, when protein synthesis was inhibited by cycloheximide, rTNF was cytotoxic for these cells but not for BT-20 cells. Cycloheximide 49-62 tumor necrosis factor Rattus norvegicus 64-68 1563013-2 1992 Since enhancement of EGF-R expression by rTNF-alpha was inhibited when cells were treated with the protein synthesis inhibitor cycloheximide, the effects of rTNF alpha may be protein-synthesis-dependent. Cycloheximide 127-140 tumor necrosis factor Rattus norvegicus 41-51 1563013-2 1992 Since enhancement of EGF-R expression by rTNF-alpha was inhibited when cells were treated with the protein synthesis inhibitor cycloheximide, the effects of rTNF alpha may be protein-synthesis-dependent. Cycloheximide 127-140 tumor necrosis factor Rattus norvegicus 157-167 3134064-5 1988 Cycloheximide inhibited the expression of PCA by U937 cells, showing that protein synthesis was necessary to mediate the effects of rTNF. Cycloheximide 0-13 tumor necrosis factor Rattus norvegicus 132-136 3496595-4 1987 Addition of cycloheximide to recombinant (r)IL-1 beta and rTNF further enhances the level of 26-kDa-protein mRNA. Cycloheximide 12-25 tumor necrosis factor Rattus norvegicus 58-62 17337591-6 2007 We have also demonstrated that the reduction of I(to) density induced by TNF-alpha was prevented by the selective inducible nitric oxide synthase (iNOS) inhibitor 1400-W, the protein synthesis inhibitor cycloheximide, the antioxidant tocopherol, and the superoxide dismutase mimetic manganese(III) tetrakis (4-benzoic acid) porphyrin. Cycloheximide 203-216 tumor necrosis factor Rattus norvegicus 73-82 3487091-4 1986 Induction of PCA by rTNF was concentration dependent (maximum, 500 units/ml), time dependent, reversible, and blocked by cycloheximide and actinomycin D, and it occurred without detectable endothelial cell damage. Cycloheximide 121-134 tumor necrosis factor Rattus norvegicus 20-24 26212436-6 2015 Cycloheximide chase analysis revealed that TNF-alpha (10 ng/ml) alone or in combination with IFN-gamma (5 ng/ml) accelerated the degradation of Cx43 protein in cultured spinal astrocytes. Cycloheximide 0-13 tumor necrosis factor Rattus norvegicus 43-52 18497737-6 2008 RESULTS: We observed that TNFalpha can induce a caspase-mediated degradation of PPARgamma proteins in the presence of cycloheximide. Cycloheximide 118-131 tumor necrosis factor Rattus norvegicus 26-34 15322069-6 2004 The effect of TNF-alpha was completely blocked by pretreatment with U-0126 or cycloheximide, but not with SB-203580. Cycloheximide 78-91 tumor necrosis factor Rattus norvegicus 14-23 16354757-4 2006 These stable WT-FAK-transfected IECs also exhibited increased resistance to apoptosis when they were exposed to TNF-alpha plus cycloheximide (TNF-alpha/CHX). Cycloheximide 127-140 tumor necrosis factor Rattus norvegicus 142-151 12818375-7 2003 Cycloheximide prevented the YC-1-enhanced TNF alpha formation, implying that new protein synthesis was required. Cycloheximide 0-13 tumor necrosis factor Rattus norvegicus 42-51 15535971-3 2004 The TNF-alpha secretion was abrogated by treatment of RBL-2H3 cells with cycloheximide, indicating the de novo synthesis of TNF-alpha, but not with polymyxin B, excluding the possible TNF-alpha induction by some contaminated lipopolysaccharides. Cycloheximide 73-86 tumor necrosis factor Rattus norvegicus 4-13 15535971-3 2004 The TNF-alpha secretion was abrogated by treatment of RBL-2H3 cells with cycloheximide, indicating the de novo synthesis of TNF-alpha, but not with polymyxin B, excluding the possible TNF-alpha induction by some contaminated lipopolysaccharides. Cycloheximide 73-86 tumor necrosis factor Rattus norvegicus 124-133 15535971-3 2004 The TNF-alpha secretion was abrogated by treatment of RBL-2H3 cells with cycloheximide, indicating the de novo synthesis of TNF-alpha, but not with polymyxin B, excluding the possible TNF-alpha induction by some contaminated lipopolysaccharides. Cycloheximide 73-86 tumor necrosis factor Rattus norvegicus 124-133 14563673-2 2004 We have recently reported that protection from TNF-alpha/cycloheximide (CHX)-induced apoptosis in epithelial cells depleted of polyamines is mediated through the inactivation of a proapoptotic mediator, JNK. Cycloheximide 57-70 tumor necrosis factor Rattus norvegicus 47-56 14563673-2 2004 We have recently reported that protection from TNF-alpha/cycloheximide (CHX)-induced apoptosis in epithelial cells depleted of polyamines is mediated through the inactivation of a proapoptotic mediator, JNK. Cycloheximide 72-75 tumor necrosis factor Rattus norvegicus 47-56 14743437-8 2004 In addition, the increase in astroglial gammaGT activity after application of TNFalpha was prevented completely by the presence of the protein synthesis inhibitor cycloheximide. Cycloheximide 163-176 tumor necrosis factor Rattus norvegicus 78-86 12869386-5 2003 Significant apoptosis was observed when CHX was given along with TNF-alpha, as indicated by a significant increase in the detachment of cells, caspase-3 activity, and DNA fragmentation. Cycloheximide 40-43 tumor necrosis factor Rattus norvegicus 65-74 12494458-4 2003 Cells were treated with TNF-alpha in the presence of cyclohexamide (CHX) to rapidly induce apoptosis. Cycloheximide 68-71 tumor necrosis factor Rattus norvegicus 24-33 9553092-2 1998 They are made susceptible to the apoptotic effect of TNF-alpha when pretreated with actinomycin D, cycloheximide or vanadate. Cycloheximide 99-112 tumor necrosis factor Rattus norvegicus 53-62 12135878-6 2002 TNFalpha alone failed to induce granulosa cell death but significantly increased the apoptotic cell number in the presence of cycloheximide. Cycloheximide 126-139 tumor necrosis factor Rattus norvegicus 0-8 12297009-4 2002 Inhibition of translation using cycloheximide greatly enhanced the apoptotic effect of TNF-alpha. Cycloheximide 32-45 tumor necrosis factor Rattus norvegicus 87-96 10843740-6 2000 LPS-induced TNF-alpha production from alveolar epithelial cells was blocked not only by cycloheximide, an inhibitor of protein translation, but also by actinomycin D, an inhibitor of gene transcription. Cycloheximide 88-101 tumor necrosis factor Rattus norvegicus 12-21 10070162-4 1999 Our results indicate that although C2 ceramide was toxic to mesangial cells, the cell death it induced differed both morphologically and biochemically from that induced by TNF-alpha in the presence of cycloheximide (CHX). Cycloheximide 216-219 tumor necrosis factor Rattus norvegicus 172-181 10070162-9 1999 Furthermore, the cleavage of cytosolic phospholipase A2 during cell death induced by C2 ceramide and by TNF-alpha in the presence of CHX showed distinctive patterns. Cycloheximide 133-136 tumor necrosis factor Rattus norvegicus 104-113 9688686-5 1998 Circulating and myocardial TNF-alpha increased at 1 and 2 h, whereas myocardial contractility was depressed at 4 and 6 h. Pretreatment with cycloheximide or dexamethasone abolished the increase in circulating and myocardial TNF-alpha and preserved myocardial contractile function. Cycloheximide 140-153 tumor necrosis factor Rattus norvegicus 27-36 9688686-5 1998 Circulating and myocardial TNF-alpha increased at 1 and 2 h, whereas myocardial contractility was depressed at 4 and 6 h. Pretreatment with cycloheximide or dexamethasone abolished the increase in circulating and myocardial TNF-alpha and preserved myocardial contractile function. Cycloheximide 140-153 tumor necrosis factor Rattus norvegicus 224-233 11406201-7 2001 TACE enzymatic activity from OGD-exposed slices was significantly inhibited by cycloheximide, suggesting that de novo synthesis of TACE contributes to TNF-alpha release after ischaemia. Cycloheximide 79-92 tumor necrosis factor Rattus norvegicus 151-160 9292957-10 1997 Treatment for 8 hours with cycloheximide (5 or 10 micrograms/mL) had no effect on the D1 mRNA level, but blocked the TNF-induced reduction of this mRNA. Cycloheximide 27-40 tumor necrosis factor Rattus norvegicus 117-120 9461593-2 1998 In this report we show that the cells can be made susceptible to the apoptotic effect of TNF-alpha when pretreated with actinomycin D, cycloheximide, or vanadate. Cycloheximide 135-148 tumor necrosis factor Rattus norvegicus 89-98 9786178-7 1998 Dexamethasone (0.5 mg/kg, s.c., 4 h) or cycloheximide (1.5 mg/kg, s.c., 6 h) significantly prevented the edema caused by des-Arg9-bradykinin (100 nmol) in rats treated with IL-1beta (81 +/- 5% and 59 +/- 3%) or TNF alpha (78 +/- 4% and 43 +/- 2%). Cycloheximide 40-53 tumor necrosis factor Rattus norvegicus 211-220 9786178-12 1998 injection of the IL-1beta or TNF alpha, produced up-regulation of B1 receptor-mediated paw edema, being this effect sensitive to dexamethasone and cycloheximide and to cyclo-oxygenase pathway. Cycloheximide 147-160 tumor necrosis factor Rattus norvegicus 29-38 9452013-5 1997 Since the increase of A-current density induced by TNF is inhibited by both the anti-TNF receptor antibody and cycloheximide treatment, the effect of TNF might be mediated through receptors and by de novo synthesis of the channel protein itself and/or modulating proteins associated with the channel activities. Cycloheximide 111-124 tumor necrosis factor Rattus norvegicus 51-54 9444616-4 1997 The increase in TNF alpha caused by stimulation of J774.2 macrophages was abolished by pretreatment of cells with (i) the protein synthesis inhibitor cycloheximide, (ii) with the selective ETA-receptor antagonists BQ-123 or BQ-485 (but not the selective ETB-receptor antagonist BQ-788), (iii) the tyrosine kinase inhibitors genistein or tyrphostin AG126, or (iv) with the glucocorticoid, dexamethasone. Cycloheximide 150-163 tumor necrosis factor Rattus norvegicus 16-25 18472868-3 1997 Dexamethasone (0.05-5 mug) and cycloheximide (6 ng), injected 2 h before LPS into the pouches, inhibited the neutrophil recruitment and the generation of the TNFalpha-like activity, while the H1-receptor antagonist mepyramine (1 and 4 mg/kg, i.p., 0.5 h before LPS) and the PAF-receptor antagonist WEB 2170 (0.05 and 1 mg/kg, i.p., 0.5 h before LPS) had no effect. Cycloheximide 31-44 tumor necrosis factor Rattus norvegicus 158-166 9048615-4 1997 Actinomycin D and cycloheximide inhibited the effects of TNF alpha on PAI-1 mRNA, suggesting that ongoing RNA and protein syntheses were required. Cycloheximide 18-31 tumor necrosis factor Rattus norvegicus 57-66 8944708-11 1996 De novo protein and RNA synthesis were required, since cycloheximide and actinomycin D also inhibited LPS-stimulated TNF-alpha release. Cycloheximide 55-68 tumor necrosis factor Rattus norvegicus 117-126